Echothiophate

Pharmaceutical drug
  • S01EB03 (WHO)
Identifiers
  • 2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodide
CAS Number
  • 6736-03-4 checkY
PubChem CID
  • 10547
DrugBank
  • DB01057 checkY
ChemSpider
  • 10107 checkY
UNII
  • 0F350BVT6S
KEGG
  • D02193 checkY
ChEBI
  • CHEBI:59849 checkY
ChEMBL
  • ChEMBL1201341 ☒N
Chemical and physical dataFormulaC9H23INO3PSMolar mass383.23 g·mol−13D model (JSmol)
  • Interactive image
  • [I-].O=P(OCC)(OCC)SCC[N+](C)(C)C
InChI
  • InChI=1S/C9H23NO3PS.HI/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5;/h6-9H2,1-5H3;1H/q+1;/p-1 checkY
  • Key:OVXQHPWHMXOFRD-UHFFFAOYSA-M checkY
 ☒NcheckY (what is this?)  (verify)

Echothiophate (Phospholine) is an irreversible acetylcholinesterase inhibitor.[1]

Uses

It is used as an ocular antihypertensive in the treatment of open angle glaucoma and, in some cases, accommodative esotropia. It is available under several trade names such as Phospholine Iodide (Wyeth-Ayerst).

Echothiophate binds irreversibly to cholinesterase. Because of the very slow rate at which echothiophate is hydrolyzed by cholinesterase, its effects can last a week or more. Adverse effects include muscle spasm and other systemic effects.

Mechanism of action

It covalently binds by its phosphate group to serine group at the active site of the cholinesterase. Once bound, the enzyme is permanently inactive and the cell has to make new enzymes.

Shortage

Wyeth Pharmaceuticals stopped manufacturing echothiophate iodide in the US in 2003. After contacting the American Academy of Ophthalmology (AAO), Wyeth rescinded their decision and, according to AAO public relations representative Michelle Stephens, the AAO and Wyeth were in talks for about a year about manufacturing it.[2]

In the meantime, a worldwide shortage of the drug has occurred.[when?][citation needed]

Chemistry

Echothiophate is made by reacting diethylchlorophosphoric acid with 2-dimethylaminoethylmercaptan, giving S-(2-dimethylaminoethyl)-O,O-diethylthiophosphate, which is alkylated by methyl iodide, forming echothiophate.[3]

References

  1. ^ Gabelt BT, Hennes EA, Seeman JL, Tian B, Kaufman PL (August 2004). "H-7 effect on outflow facility after trabecular obstruction following long-term echothiophate treatment in monkeys". Invest. Ophthalmol. Vis. Sci. 45 (8): 2732–6. doi:10.1167/iovs.04-0083. PMID 15277498.
  2. ^ "Eurotimes article: "Echothiophate iodide shortage leaves US specialists struggling to find alternative for acute cases"". Archived from the original on 2006-06-19. Retrieved 2006-08-13.
  3. ^ H.M. Fitch, U.S. patent 2,911,430 (1959)
  • v
  • t
  • e
Drugs used for glaucoma preparations and miosis (S01E)
SympathomimeticsParasympathomimetics
muscarinic
muscarinic/nicotinic
acetylcholinesterase inhibitors
Carbonic anhydrase inhibitors/
(sulfonamides)Beta blocking agentsProstaglandin analogues (F)Other agents
  • v
  • t
  • e
Enzyme
(modulators)
ChATTooltip Choline acetyltransferase
  • Inhibitors: 1-(-Benzoylethyl)pyridinium
  • 2-(α-Naphthoyl)ethyltrimethylammonium
  • 3-Chloro-4-stillbazole
  • 4-(1-Naphthylvinyl)pyridine
  • Acetylseco hemicholinium-3
  • Acryloylcholine
  • AF64A
  • B115
  • BETA
  • CM-54,903
  • N,N-Dimethylaminoethylacrylate
  • N,N-Dimethylaminoethylchloroacetate
AChETooltip Acetylcholinesterase
BChETooltip Butyrylcholinesterase
Transporter
(modulators)
CHTTooltip Choline transporter
VAChTTooltip Vesicular acetylcholine transporter
Release
(modulators)
Inhibitors
  • SNAP-25Tooltip Synaptosomal-associated protein 25 inactivators: Botulinum toxin (A, C, E)
  • VAMPTooltip Vesicle-associated membrane protein inactivators: Botulinum toxin (B, D, F, G)
Enhancers
See also
Receptor/signaling modulators
Muscarinic acetylcholine receptor modulators
Nicotinic acetylcholine receptor modulators